Granzyme B releases vascular endothelial growth factor from extracellular matrix and induces vascular permeability

Laboratory Investigation

Volumn 94, Issue 7, 2014, Pages 716-725

  Hendel, Alon ^a   Hsu, Ivy ^a   Granville, David J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

fibronectin; granzyme B; inflammation; vascular permeability; VEGF

Indexed keywords

APROTININ; FIBRONECTIN; GRANZYME B; MATRIX PROTEIN; N (5 BENZAMIDO 4 OXO 6 PHENYLHEXANOYL)PROLINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME RELEASE; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATORY DISEASE; MOUSE; NONHUMAN; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES, BLOCKING; BLOTTING, WESTERN; CAPILLARY PERMEABILITY; CELLS, CULTURED; EXTRACELLULAR MATRIX; FIBRONECTINS; GRANZYMES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERSENSITIVITY, DELAYED; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84903536850     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.62     Document Type: Article

References (46)

1. Arroyo AG, Iruela-Arispe ML. Extracellular matrix, inflammation, and the angiogenic response. Cardiovasc Res 2010;86:226-235.
2. Nagy JA, Dvorak AM, Dvorak HF. Vascular hyperpermeability, angiogenesis, and stroma generation. Cold Spring Harb Perspect Med 2012;2:a006544.
3. Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 2007;10:149-166.
4. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007;2:251-275.
5. Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med 2012;2: a006502.
6. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007;130:691-703.
7. Houck KA, Leung DW, Rowland AM, et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992;267:26031-26037.
8. Lee S, Jilani SM, Nikolova GV, et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 2005;169:681-691.
9. Ebrahem Q, Chaurasia SS, Vasanji A, et al. Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am J Pathol 2010;176: 496-503.
10. Wijelath ES, Murray J, Rahman S, et al. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ Res 2002;91:25-31.
11. Wijelath ES, Rahman S, Namekata M, et al. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/ matrix protein synergism. Circ Res 2006;99:853-860.
12. Martino MM, Hubbell JA. The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. FASEB J 2010;24:4711-4721.
13. Martino MM, Tortelli F, Mochizuki M, et al. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci Transl Med 2011;3:100ra89.
14. Hendel A, Hiebert PR, Boivin WA, et al. Granzymes in age-related cardiovascular and pulmonary diseases. Cell Death Differ 2010;17: 596-606.
15. Boivin WA, Cooper DM, Hiebert PR, et al. Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab Invest 2009;89:1195-1220.
16. Hiebert PR, Granville DJ. Granzyme B in injury, inflammation, and repair. Trends Mol Med 2012;18:732-741.
17. Kondo H, Hojo Y, Tsuru R, et al. Elevation of plasma granzyme B levels after acute myocardial infarction. Circ J 2009;73:503-507.
18. Kummer JA, Tak PP, Brinkman BM, et al. Expression of granzymes A and B in synovial tissue from patients with rheumatoid arthritis and osteoarthritis. Clin Immunol Immunopathol 1994;73:88-95.
19. Ang LS, Boivin WA, Williams SJ, et al. Serpina3n attenuates granzyme B-mediated decorin cleavage and rupture in a murine model of aortic aneurysm. Cell Death Dis 2011;2:e209.
20. Chamberlain CM, Ang LS, Boivin WA, et al. Perforin-independent extracellular granzyme B activity contributes to abdominal aortic aneurysm. Am J Pathol 2010;176:1038-1049.
21. Hiebert PR, Boivin WA, Abraham T, et al. Granzyme B contributes to extracellular matrix remodeling and skin aging in apolipoprotein E knockout mice. Exp Gerontol 2011;46:489-499.
22. Hiebert PR, Wu D, Granville DJ. Granzyme B degrades extracellular matrix and contributes to delayed wound closure in apolipoprotein E knockout mice. Cell Death Differ 2013;20:1404-1414.
23. Omoto Y, Yamanaka K, Tokime K, et al. Granzyme B is a novel interleukin-18 converting enzyme. J Dermatol Sci 2010;59:129-135.
24. Afonina IS, Tynan GA, Logue SE, et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1alpha. Mol Cell 2011;44:265-278.
25. Boivin WA, Shackleford M, Vanden Hoek A, et al. Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-beta1. PLoS One 2012;7:e33163.
26. Hendel A, Granville DJ. Granzyme B cleavage of fibronectin disrupts endothelial cell adhesion, migration and capillary tube formation. Matrix Biol 2013;32:14-22.
27. Willoughby CA, Bull HG, Garcia-Calvo M, et al. Discovery of potent, selective human granzyme B inhibitors that inhibit CTL mediated apoptosis. Bioorg Med Chem Lett 2002;12:2197-2200.
28. Macri L, Silverstein D, Clark RA. Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv Drug Deliv Rev 2007;59:1366-1381.
29. Keyt BA, Berleau LT, Nguyen HV, et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996;271:7788-7795.
30. Kurtagic E, Jedrychowski MP, Nugent MA. Neutrophil elastase cleaves VEGF to generate a VEGF fragment with altered activity. Am J Physiol Lung Cell Mol Physiol 2009;296:L534-L546.
31. Miles AA, Miles EM. Vascular reactions to histamine, histamineliberator and leukotaxine in the skin of guinea-pigs. J Physiol 1952;118:228-257.
32. Maharaj AS, Saint-Geniez M, Maldonado AE, et al. Vascular endothelial growth factor localization in the adult. Am J Pathol 2006;168:639-648.
33. Elias PM, Arbiser J, Brown BE, et al. Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: implications for the pathogenesis of psoriasis. Am J Pathol 2008;173:689-699.
34. Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003;102:161-168.
35. Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell 2010;21:687-690.
36. Weis SM, Cheresh DA. Pathophysiological consequences of VEGFinduced vascular permeability. Nature 2005;437:497-504.
37. Ozawa CR, Banfi A, Glazer NL, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004;113:516-527.
38. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-744.
39. Belotti D, Paganoni P, Manenti L, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003;63:5224-5229.
40. Aplin AC, Zhu WH, Fogel E, et al. Vascular regression and survival are differentially regulated by MT1-MMP and TIMPs in the aortic ring model of angiogenesis. Am J Physiol Cell Physiol 2009;297: C471-C480.
41. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, et al. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999;274: 29568-29571.
42. Pozzi A, Moberg PE, Miles LA, et al. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci USA 2000;97:2202- 2207.
43. Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003;3:589-601.
44. Casciola-Rosen L, Garcia-Calvo M, Bull HG, et al. Mouse and human granzyme B have distinct tetrapeptide specificities and abilities to recruit the bid pathway. J Biol Chem 2007;282:4545-4552.
45. Honda T, Egawa G, Grabbe S, et al. Update of immune events in the murine contact hypersensitivity model: toward the understanding of allergic contact dermatitis. J Invest Dermatol 2013;133: 303-315.
46. Pardo J, Wallich R, Ebnet K, et al. Granzyme B is expressed in mouse mast cells in vivo and in vitro and causes delayed cell death independent of perforin. Cell Death Differ 2007;14:1768-1779.